Trial Profile

A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active Non-Infectious Intermediate-, Posterior-, and Panuveitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brepocitinib (Primary)
Indications Intermediate uveitis; Panuveitis; Posterior uveitis
Focus Adverse reactions; Proof of concept
Acronyms NEPTUNE
Sponsors Priovant Therapeutics

Most Recent Events

26 Nov 2024 Status changed from active, no longer recruiting to completed.
23 Sep 2024 Patient-level macular edema results at week 24 from the NEPTUNE Study will be presented at the American Academy of Ophthalmology (AAO) annual meeting October 18-21 in Chicago.
23 Sep 2024 Results presented in the Roivant Sciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com